gov fund delay set
thermo fisher report modestli softer-than-expect result
organ revenu growth comp expect jpme
buy-sid mainli due unexpect delay fund releas
high-end equip china particularli government-control state
enterpris academ institut late quarter believ
disproport impact fei segment growth led lss
organ sd organ lp organ ai organ
saw continu slowdown due aforement china fund delay
bottom line adjust ep line consensu
lower-than-expect opm expans bp due acquisit growth
invest fx headwind off-set share buyback
look ahead compani issu guidanc call revenu
organ ep bracket jpme/street
low end long-term outlook
appear typic conserv start year start
end although manag note earli emb potenti
neg posit impact china coronaviru epidem step
back mainli weigh china fund delay although
heard compani echo dynam earli
earn cycl telegraph confer earlier
month henc sell-off view although result outsid ai
remain robust initi guidanc set compani anoth
beat-and-rais year especi industri comp eas along
resili macro risk capit deploy option next
three year continu like set-up reiter overweight rate
increas decemb pt vs prior
quarter weigh china fund delay tough comp
especi fei revenu came modestli jpme/street
organ growth comp
comp due fund releas slowdown china sd vs
comp lss vs comp lp vs comp led
pharma servic research safeti channel end market biopharma
grew broad-bas strength clinic msd led immuno-dx
clinic dx healthcar channel academ lsd industri remain
weak -msd dd comp especi fei geograph europ
grew hsd na msd apac lsd china lsd vs expect
msd due tough comp fund delay row msd
bottom line adj ep line jpme/street
lower-than-expect opm expans bp due acquisit growth
invest fx headwind off-set share buyback
sourc style exposur morgan quantit deriv strategi tabl compani data morgan estim
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
summari invest thesi valuat
continu fire cylind organ
inorgan end market continu look exceedingli
healthi despit linger macro/fx/tariff risk
guidanc framework set stage beat-and-
rais year continu like setup go forward
reiter ow rate
price target price target deriv
discount cash flow analysi capm-deriv
wacc discount rate termin growth
million
cash-flow oper
margin growth
sourc perform driver bloomberg morgan quantit deriv strategi tabl compani data morgan estim
guidanc line expect typic conserv leav
upsid anoth beat-and-rais year along quarter also
provid initi guidanc framework call call revenu
organ ep also bracket jpme/street
appear typic conserv start last year
guid end deliv manag embed usual
element conservat start year remain highli posit
regard tool end market trend abil drive outsiz growth
market innov share gain commerci execut chang
lt outlook organ growth specif china manag
expect high-teen growth equip purchas delay expect
recov gradual year although manag note earli
emb potenti impact china coronaviru epidem could
impact sd segment china revenu total revenu
term potenti headwind patient travel hospit also
tailwind develop rapid test includ framework also
expect fx headwind larg acquisit
contribut net revenu headwind ap divestitur bp
opm expans bp impact growth invest bp
impact pct dx contract extens net interest expens
last year due continu debt paydown/refinanc adjust tax rate
improv last year dilut share count
includ share buyback year term linear
one fewer sell day two extra day day bring
revenu contribut organ growth expect coupl point
lower fy averag due also tough fei comp consist prior year
 embed outlook funnel still character
full on-going investor interest potenti deal see
potenti accret math manag downplay interest long-
read sequenc market focu organ invest
genet analysi busi although could clearli chang time
maintain overweight overal quarter mainli weigh china
govern fund delay although heard compani echo
dynam result outsid ai remain robust difficult comp
initi guidanc set compani anoth beat-and-rais
year especi industri comp becom easier long-term believ
tmo strong product leadership key life scienc applic unmatch
commerci scope scale posit drive continu above-market
organ growth enhanc acquisit brammer see
take well deep dive cell gene therapi
biomanufactur along resili macro risk given broad-bas
busi high consum mix long runway margin expans target
bp annual capit deploy option plan
next three year continu like outlook reiter overweight
rate increas decemb pt vs prior
lab product servic
 share count
invest thesi valuat risk
continu fire cylind organ inorgan end
market continu look exceedingli healthi despit linger
macro/fx/tariff risk guidanc framework set stage
beat-and-rais year continu like setup go forward reiter ow
price target price target deriv discount cash
flow analysi capm-deriv wacc discount rate termin
growth
risk rate price
downsid risk includ deterior global industri demand slow
pharma demand softer academ demand expect given increas
nih budget technolog shortfal includ inabl introduc
competit instrument consum time effect manner
lab product servic
good sold
chang gross margin y/i bp
chang op margin y/i bp
pv termin valu
perpetu growth rate
enterpris valu
thermo fisher scientif summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect research analyst person view subject secur issuer
part research analyst compens directli indirectli relat specif recommend
view express research analyst report korea-bas research analyst list front cover applic
also certifi per kofia requir analysi made good faith view reflect opinion
without undu influenc intervent
author name within report research analyst unless otherwis specifi europ sector specialist may shown
report contact author report part research depart
